<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; DENTSPLY International Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/dentsply-international-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALGN) Align Technology Posts Solid First Quarter Earnings</title>
		<link>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568</link>
		<comments>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:05:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[American Strategic Income Portfolio Inc]]></category>
		<category><![CDATA[ASP]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99568</guid>
		<description><![CDATA[Align Technology (ALGN) reported first quarter 2012 EPS of 26 cents, which was 30% higher than the year-ago level. Adjusting for certain one-time items, the adjusted EPS came in at 27 cents, beating the Zacks Consensus Estimate of 22 cents as well as the year-ago quarter adjusted EPS of 21 cents. The adjusted EPS also surpassed the company’s guidance range of 19?21 cents. Total revenue increased 28.7% year over year to $135.1 million in the quarter, exceeding the Zacks Consensus Estimate of $129 million and the company’s guidance of $125.4?$127.9 million. Total Invisalign clear aligner revenue came in at $123.3 million, up 17.6% year over year, driven by case shipments of 85.3 thousand (up 19.5%) during the quarter. Scanner and CAD/CAM services revenues were $11.8 million in the reported quarter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) DENTSPLY International &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/12/01/xray-dentsply-international-bull-of-the-day-2/87860</link>
		<comments>http://www.stockbloghub.com/2011/12/01/xray-dentsply-international-bull-of-the-day-2/87860#comments</comments>
		<pubDate>Thu, 01 Dec 2011 14:53:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87860</guid>
		<description><![CDATA[We reaffirm our Outperform recommendation on DENTSPLY International (XRAY). Its third-quarter fiscal 2011 revenues and earnings outperformed the Zacks Consensus Estimates. Revenues were boosted by internal growth, foreign exchange tailwind and Astra Tech acquisition. The company beefed up its earnings guidance for fiscal 2011 based on stable market conditions and the contributions of Astra Tech. DENTSPLY should benefit from the gradual recovery in the global dental market. The company&#8217;s diversified product range and significant investment in product innovation should help it expand its share of the dental implant market. Moreover, the acquisition of Astra Tech has reinforced its foothold in the global dental market and provided opportunities for attractive synergies. We also feel that the stock offers attractive upside potential at the current level. DENTSPLY INTL (XRAY): Free Stock Analysis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/xray-dentsply-international-bull-of-the-day-2/87860/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALGN) Align Technology Beats The Street &#8211; Margins Lag</title>
		<link>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166</link>
		<comments>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:41:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[American Strategic Income Portfolio Inc]]></category>
		<category><![CDATA[ASP]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86166</guid>
		<description><![CDATA[Align Technology (ALGN) reported third quarter 2011 adjusted EPS of 27 cents, beating the Zacks Consensus Estimate of 20 cents as well as the year-ago quarter adjusted EPS by 2 cents. Reported EPS was also ahead of the company’s guidance range of 17-20 cents. Total revenue increased 31.3% year over year to $125.9 million, exceeding the Zacks Consensus Estimate of $122 million and the company’s guidance of $118-$123 million. Total Invisalign revenue came in at $114.3 million, up 19.1% year over year driven by case shipments of 79.4 thousand (up 19.8%) during the quarter. Align witnessed improved sales performance during the reported quarter. This positive growth was attributable to increased Invisalign case volume in North American Orthodontists and International doctors, strong growth of Invisalign Teen and higher earnings on the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) DENTSPLY International &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/09/27/xray-dentsply-international-bull-of-the-day/84133</link>
		<comments>http://www.stockbloghub.com/2011/09/27/xray-dentsply-international-bull-of-the-day/84133#comments</comments>
		<pubDate>Tue, 27 Sep 2011 17:46:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84133</guid>
		<description><![CDATA[We upgrade our recommendation on DENTSPLY International (XRAY) to Outperform based on our improved visibility on the stock. Its second-quarter fiscal 2011 revenues and earnings topped the Zacks Consensus Estimates. Revenues and profit were boosted by internal growth and a foreign exchange tailwind. The company beefed up its earnings guidance for fiscal 2011 based on a stable-to-improving market conditions. DENTSPLY should benefit from the gradual recovery in the global dental market. The company&#8217;s diversified product range and significant investment in product innovation should help it expand its share of the dental implant market. Moreover, the acquisition of Astra Tech has reinforced its foothold in the global dental market and provided opportunities for attractive synergies. We also feel that the stock offers attractive upside potential at the current level. DENTSPLY INTL ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/27/xray-dentsply-international-bull-of-the-day/84133/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds</title>
		<link>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075</link>
		<comments>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:43:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79075</guid>
		<description><![CDATA[Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic&#8217;s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership, Apax exclusively focuses on long-term investment in growth companies. The acquisition of Kinetic is part of Apax’s intention to support deals in the financial &#38; business services, healthcare, media, retail &#38; consumer and technology sectors. However, probably its budget doesn’t permit such a big acquisition at this point, so Apax teamed up with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) to get the deal done. As per the terms of the agreement, Kinetic’s shareholders will receive $68.50 in cash for each share of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) DENTSPLY Grabs Astra Tech for $1.8 Billion</title>
		<link>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293</link>
		<comments>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:03:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77293</guid>
		<description><![CDATA[In a bid to bolster its foothold in the global dental market, leading dental products maker DENTSPLY International (XRAY) has agreed to buy Astra Tech, the dental implant division of multinational drug major AstraZeneca PLC (AZN), for $1.8 billion in cash. The Anglo-Swiss pharmaceutical giant is selling the dental unit to renew focus on its core prescription drug business. Other financial terms of the deal were not disclosed by the entities. The transaction, which is subject to antitrust clearance, is expected to complete by end-2011. Morgan Stanley (MS) is acting as financial advisor to DENTSPLY on the deal. DENTSPLY plans to finance the acquisition with cash, commercial paper and long-term debt. The company had cash and cash equivalents of roughly $575.3 million in first-quarter fiscal 2011. Compelling Prospect Sweden-based Astra ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(APOG) Company News for June 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238</link>
		<comments>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238#comments</comments>
		<pubDate>Thu, 23 Jun 2011 16:06:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[General Building Materials]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[APOG]]></category>
		<category><![CDATA[Apogee Enterprises Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FDX]]></category>
		<category><![CDATA[FedEx Corporation]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Jabil Circuit Inc.]]></category>
		<category><![CDATA[JBL]]></category>
		<category><![CDATA[RBN]]></category>
		<category><![CDATA[Robbins & Myers Inc]]></category>
		<category><![CDATA[SCBT]]></category>
		<category><![CDATA[SCBT Financial Corporation]]></category>
		<category><![CDATA[Western Refining Inc.]]></category>
		<category><![CDATA[WNR]]></category>
		<category><![CDATA[XRAY]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77238</guid>
		<description><![CDATA[•    Shares of Robbins &#38; Myers, Inc. (NYSE:RBN) jumped 8.77% on strong fiscal third-quarter profits. The energy equipment supplier said strong customer demand and the recent acquisition of oilfield services has helped the company&#8217;s increase its profits •    Shares of Jabil Circuit (NYSE:JBL) gained 3.18% to close at $19.45 after the company posted earnings that doubled from the previous year. The company also initiated buyback of $200 million of stock •    Apogee Enterprises (NASDAQ:APOG) reported a Q1 loss of $0.08 per share. Revenues increased 7.2% year-over-year to $153.3 million, surpassing the Zacks Consensus Estimate of $147.0 million •    Share prices of shipping service giant FedEx (NYSE:FDX) rose 2.59% after the company posted earnings that came in above analysts’ expectations. The company also projected robust earnings growth for 2012 •    DENTSPLY ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) DENTSPLY International Analysts Initiate Coverage as Neutral</title>
		<link>http://www.stockbloghub.com/2009/12/31/xray-dentsply-international-analysts-initiate-coverage-as-neutral/24005</link>
		<comments>http://www.stockbloghub.com/2009/12/31/xray-dentsply-international-analysts-initiate-coverage-as-neutral/24005#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:30:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24005</guid>
		<description><![CDATA[We recently initiated coverage on DENTSPLY International Inc. (XRAY) with a Neutral recommendation. We rate the stock Neutral with a target price of $37 based on a P/E of 18.3x our 2010 EPS estimate of $2.02. DENTSPLY reported third quarter fiscal 2009 earnings per share of 44 cents, in line with the Zacks Consensus Estimate but slightly lower than the year-ago figure of 46 cents. The company’s sales were roughly flat year over year at $531.0 million. Excluding the precious metal content, net sales increased 1.1% year over year. Excluding the precious metal content, gross margin in the third quarter declined 210 basis points (bps) year over year to 55.3%. However, the company’s cost-control initiatives helped it increase the operating margin 220 bps year over year to 18.8%. DENTSPLY expects ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/xray-dentsply-international-analysts-initiate-coverage-as-neutral/24005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) Dentsply International Reports In-Line</title>
		<link>http://www.stockbloghub.com/2009/11/01/xray-dentsply-international-reports-in-line/19280</link>
		<comments>http://www.stockbloghub.com/2009/11/01/xray-dentsply-international-reports-in-line/19280#comments</comments>
		<pubDate>Sun, 01 Nov 2009 22:36:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19280</guid>
		<description><![CDATA[Dentsply International Inc. (XRAY) reported third quarter earnings per share of 44 cents, in-line with the Zacks Consensus Estimate, but lower than the year-ago earnings of 46 cents. Net sales in the reported quarter increased 0.2% year over year to $531.0 million. Excluding the precious metal content, net sales increased 1.1% year over year to $493.6 million. The marginal increase in net sales indicates that the global dental market is in the earlier stages of recovery. Not being a life-sustaining product, the dental market was badly affected by the economic downturn that resulted in patients deferring their adoption. Excluding the precious metal content, gross margin in the reported quarter was 55.3%, declining 210 basis points (bps) year over year. Selling, general and administrative expenses, as a percentage of sales, declined ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/xray-dentsply-international-reports-in-line/19280/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

